Tazarotene: Therapeutic Strategies in the Treatment of Psoriasis, Acne and Photoaging
- 23 April 2004
- journal article
- review article
- Published by S. Karger AG in Skin Pharmacology and Physiology
- Vol. 17 (3) , 111-118
- https://doi.org/10.1159/000077236
Abstract
Tazarotene is a member of the new generation of receptor-selective, synthetic retinoids for the topical treatment of mild to moderate plaque psoriasis, acne vulgaris and photoaging. Though they are effective in monotherapy, clinical studies with a focus on novel combination treatments and a comparison of different agents for these skin disorders are accumulating. The concomitant use of tazarotene with a mid-potency or high-potency corticosteroid enhances the efficacy in psoriatic plaques and reduces the risk of steroid-induced skin atrophy. Combining phototherapy with adjunctive tazarotene accelerates the clinical response and reduces the cumulative UVB or PUVA exposure load. Tazarotene applied once daily is superior to adapalene monotherapy in acne vulgaris and is efficacious in the treatment of photodamage. Novel therapeutic regimens such as short-contact therapy have been developed for both acne and psoriasis in order to diminish the major adverse events like pruritus, burning, local skin irritation and erythema.Keywords
This publication has 49 references indexed in Scilit:
- Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment: comparison of maintenance treatmentsInternational Journal of Dermatology, 2001
- A multicentre, single-blind, randomized comparison of a fixed clindamycin phosphate/tretinoin gel formulation (Velac®) applied once daily and a clindamycin lotion formulation (Dalacin T®) applied twice daily in the topical treatment of acne vulgarisBritish Journal of Dermatology, 2000
- Combination treatment of psoriasis with photochemotherapy and tazarotene gel, a receptor-selective topical retinoidBritish Journal of Dermatology, 1999
- Clinical Pharmacokinetics and Drug Metabolism of TazaroteneClinical Pharmacokinetics, 1999
- AdapaleneDrugs, 1997
- A CBP Integrator Complex Mediates Transcriptional Activation and AP-1 Inhibition by Nuclear ReceptorsCell, 1996
- A comparison of the efficacy and safety of adapalene gel 0.1% and tretinoin gel 0.025% in the treatment of acne vulgaris: A multicenter trialJournal of the American Academy of Dermatology, 1996
- Systemic treatment for severe atopic dermatitisJournal of Dermatological Treatment, 1996
- New understandings of the pathogenesis of acneJournal of the American Academy of Dermatology, 1995
- Response of psoriasis to a new topical retinoid, AGN 190168Journal of the American Academy of Dermatology, 1994